The DOI matches its Crossref record; 142 of the 158 references it cites were found in a registry or an index; 50 of the 167 sources its claims cite were checked for support.
Cognitive Behavioral Therapy and Acceptance and Commitment Therapy for the Discontinuation of Long-Term Benzodiazepine Use in Insomnia and Anxiety Disorders
Open accessAbstract
Benzodiazepines have proven to be highly effective for treating insomnia and anxiety. Although considered safe when taken for a short period of time, a major risk–benefit dilemma arises in the context of long-term use, relating to addiction, withdrawal symptoms, and potential side effects. For these reasons, benzodiazepines are not recommended for treating chronic sleep disorders, anxiety disorders, nor for people over the age of 65, and withdrawal among long-term users is a public health issue. Indeed, only 5% of patients manage to discontinue using these drugs on their own. Even with the help of a general practitioner, this rate does not exceed 25 to 30% of patients, of which approximately 7% manage to remain drug-free in the long term. Cognitive Behavioral Therapies (CBT) offer a crucial solution to this problem, having been shown to increase abstinence success to 70–80%. This article examines traditional and novel CBT techniques in this regard, such as Acceptance and Commitment Therapy, which address both the underlying condition (insomnia/anxiety) and the substance-related disorder. The theoretical framework and evidence supporting the use of these approaches are reviewed. Finally, current research gaps are discussed, and key research perspectives are proposed. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
Overview
CoChat Summary
## TL;DR
This review argues that long-term benzodiazepine withdrawal is difficult and that cognitive behavioral therapy (CBT), including newer forms such as acceptance and commitment therapy (ACT), can improve discontinuation success when paired with tapering. The paper mainly synthesizes prior studies and concludes that CBT should be used before and during deprescribing for patients with insomnia or anxiety disorders.
## Key findings
- The paper states that only 5% of patients discontinue benzodiazepines on their own, and that with a general practitioner the rate rises to 25–30%, with about 7% remaining drug-free long term.
- In the reviewed literature, brief interventions for discontinuation had an overall success rate of 25–40%, versus 5% for waiting list or treatment as usual.
- The paper reports eight RCTs comparing taper alone vs taper plus CBT, plus two publications with long-term outcomes; among these, five out of seven studies showed greater success with CBT plus tapering.
- Specific examples reported for CBT plus tapering include: panic disorder (80% vs 40%, 75% vs 23%, 62.5% vs 12.5% at 6 months), generalized anxiety disorder (75% vs 35% at 12 months), insomnia (85% vs 48% and 70% vs 25% at 12 months), and panic disorder at 24 months (75% vs 30%). For insomnia, relapse was still seen at 5 years, but benefit remained (50% vs 32%).
## Methods
- Narrative review of the theoretical and clinical-trial evidence on CBT and ACT for discontinuing long-term benzodiazepine use in insomnia and anxiety disorders.
- The authors searched Medline, PsycINFO, and the Cochrane Collaboration Central Register of Controlled Trials in November 2020, and also used citations from studies, reviews, and meta-analyses of benzodiazepine-reduction interventions.
- The review synthesized RCTs and meta-analyses on taper programs, CBT, and ACT, with attention to insomnia, anxiety disorders, withdrawal, and abstinence outcomes.
## Limitations
- The paper explicitly states that studies on CBT interventions are scarce: nine RCTs over 30 years of research, and that the number of studies on ACT for benzodiazepine withdrawal is insufficient to establish a recommendation.
- It also states that no study has assessed the effectiveness of ACT on BZD withdrawal as a primary outcome, and that evidence for ACT in this area is limited to one pilot study for insomnia associated with sleeping pill addiction.
- Evident from the text: this is a review, not a new clinical trial, so its conclusions depend on the quality and heterogeneity of the included studies; the paper itself notes that withdrawal programs, follow-up duration, and patient definitions vary greatly across studies.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
32 Valid · 11 Not valid · 49 Not checked · 43 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“or quadruples (62.5% versus 12.5%) [119] the number of drug-free patients at 6 months.”
§ Cognitive Behavioral Therapy and Acceptance and Commitment Therapy for the Discontinuation of Long-Term Benzodiazepine Use in Insomnia and Anxiety Disorders > 3. Cognitive Behavioral Therapy (CBT) for Discontinuing Long-Term Benzodiazepine Use in Insomnia and Anxiety Disorders > 3.4. Effectiveness of Adding CBT to Taper Programs
What the sources say
- Disputedcites [119] Otto, 2010, Efficacy of CBT for Benzodiazepine Discontinuation in Patients with Panic Disorder: Further Evaluation, Behav. Res. Ther. sourceExperimental — accuracy not yet measured
The Results > BZ-Free Status section reports 62.5% benzodiazepine-free with CBT at six months, but 12.5% was the rate for taper plus relaxation, not taper alone. The taper-alone rate was 26.7%, so the stated comparison and “quadruples” description do not match the paper. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“BZDs are effective in the treatment of anxiety disorders [2,3,4] and insomnia [5,6].”
§ Cognitive Behavioral Therapy and Acceptance and Commitment Therapy for the Discontinuation of Long-Term Benzodiazepine Use in Insomnia and Anxiety Disorders > 1. Introduction Benzodiazepines and related drugs (Z-drugs) (BZD) are a class of psychotropic drugs with an effect similar to that of alcohol: they amplify the activity of GABA-A receptors, producing hypnotic, anxiolytic, muscle relaxant, anticonvulsant, and amnesic effects [1]. BZDs are effective in the treatment of anxiety disorders [2,3,4] and insomnia [5,6]. Their duration of action depends on their elimination half-life (the time taken by the body to eliminate half of the dose), which is classified as short (1–12 h), medium (12–40 h), and long (>40 h). These substances require a prescription and are intended to be used under the surveillance of a medical practitioner. They are recommended by health authorities as a short-term treatment [7] and are therefore not intented to be used for the treatment of chronic anxiety or insomnia. However, such prescription recommendations, alone, have not prevented their widespread overuse, and the subsequent development of psychological addictions. This article aims to (i) describe the global epidemiology of BZD use with a particular focus on the situation in France, and the issues associated with long-term BZD use such as side effects, withdrawal syndrome and ecological impact, (ii) review the public health strategies proposed in European countries to limit the use of BZD as well as the therapeutic interventions available for promoting BZD withdrawal, and (iii) provide an up-to-date overview of the theoretical framework and the clinical trial-based evidence supporting the use of traditional and new generations of Cognitive and Behavioral Therapy (CBT) for successful long-term BZD use cessation, with a specific interest in Acceptance and Commitment Therapy (ACT).
What the sources say
- Partly supportedcites [2] Slee, 2019, Pharmacological Treatments for Generalised Anxiety Disorder: A Systematic Review and Network Meta-Analysis, Lancet sourceExperimental — accuracy not yet measured
The Discussion says benzodiazepines have a good effect on reducing anxiety symptoms in the network analysis. However, the analysis covers generalised anxiety disorder; it does not establish effectiveness across anxiety disorders generally. No page number is available in our copy. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [3] Bandelow, 2015, Efficacy of Treatments for Anxiety Disorders: A Meta-Analysis, Int. Clin. Psychopharmacol. source
- Supportedcites [4] Stahl, 2002, Don’t Ask, Don’t Tell, but Benzodiazepines Are Still the Leading Treatments for Anxiety Disorder, J. Clin. Psychiatry source
The 'Combining Independent Mechanisms to Enhance Therapeutic Results' section says benzodiazepines may provide rapid relief, boost early treatment efficacy, and relieve breakthrough anxiety. This supports the attributed claim that they are effective for treating anxiety disorders, while acknowledging limitations. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These symptoms are more severe following withdrawal from short rather than long half-life BZDs [39,40,41,42,43].”
§ Cognitive Behavioral Therapy and Acceptance and Commitment Therapy for the Discontinuation of Long-Term Benzodiazepine Use in Insomnia and Anxiety Disorders > 2. Benzodiazepine Use and Abuse > 2.2. Low Benefit-to-Risk Ratio
What the sources say
- Not checked — no full text of the sourcecites [39] Lapierre, 1981, Benzodiazepine Withdrawal, Can. J. Psychiatry source
- Partly supportedcites [40] Morgan, 1982, Anxiety Caused by a Short-Life Hypnotic, Br. Med. J. sourceExperimental — accuracy not yet measured
The Subjects, methods, and results section reports that anxiety peaked sooner after withdrawal of the shorter-lived triazolam than after withdrawal of loprazolam. The Comment likewise says faster elimination produces earlier rebound, but neither passage establishes that withdrawal symptoms are generally more severe with short- than long-half-life benzodiazepines. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [41] Soldatos, 1999, Tolerance and Rebound Insomnia with Rapidly Eliminated Hypnotics: A Meta-Analysis of Sleep Laboratory Studies, Int. Clin. Psychopharmacol. source
- Not checked — no full text of the sourcecites [42] Kales, 1983, Rebound Insomnia and Rebound Anxiety: A Review, Pharmacology source
- Not checked — no full text of the sourcecites [43] Gillin, 1989, Rebound Insomnia: A Critical Review, J. Clin. Psychopharmacol. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“BZDs are effective in the treatment of anxiety disorders [2,3,4] and insomnia [5,6].”
§ Cognitive Behavioral Therapy and Acceptance and Commitment Therapy for the Discontinuation of Long-Term Benzodiazepine Use in Insomnia and Anxiety Disorders > 1. Introduction Benzodiazepines and related drugs (Z-drugs) (BZD) are a class of psychotropic drugs with an effect similar to that of alcohol: they amplify the activity of GABA-A receptors, producing hypnotic, anxiolytic, muscle relaxant, anticonvulsant, and amnesic effects [1]. BZDs are effective in the treatment of anxiety disorders [2,3,4] and insomnia [5,6]. Their duration of action depends on their elimination half-life (the time taken by the body to eliminate half of the dose), which is classified as short (1–12 h), medium (12–40 h), and long (>40 h). These substances require a prescription and are intended to be used under the surveillance of a medical practitioner. They are recommended by health authorities as a short-term treatment [7] and are therefore not intented to be used for the treatment of chronic anxiety or insomnia. However, such prescription recommendations, alone, have not prevented their widespread overuse, and the subsequent development of psychological addictions. This article aims to (i) describe the global epidemiology of BZD use with a particular focus on the situation in France, and the issues associated with long-term BZD use such as side effects, withdrawal syndrome and ecological impact, (ii) review the public health strategies proposed in European countries to limit the use of BZD as well as the therapeutic interventions available for promoting BZD withdrawal, and (iii) provide an up-to-date overview of the theoretical framework and the clinical trial-based evidence supporting the use of traditional and new generations of Cognitive and Behavioral Therapy (CBT) for successful long-term BZD use cessation, with a specific interest in Acceptance and Commitment Therapy (ACT).
What the sources say
- Not checked — no full text of the sourcecites [5] Morgan, 2021, Psychological and Pharmacological Treatments for Insomnia: Blending for Patient Benefit, Sleep Med. Rev. source
- Supportedcites [6] Buscemi, 2007, The Efficacy and Safety of Drug Treatments for Chronic Insomnia in Adults: A Meta-Analysis of RCTs, J. Gen. Intern. Med. source
The Abstract concludes that benzodiazepines are effective treatments for chronic insomnia. The Discussion likewise reports effectiveness, while noting that the evidence is most relevant to short-term treatment of chronic insomnia. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Nevertheless, two reviews show no added value of melatonin substitution [66,67] and, to the best of our knowledge, arguments regarding the benefit of diazepam substitution are mostly theoretical (not evidence-based).”
§ Cognitive Behavioral Therapy and Acceptance and Commitment Therapy for the Discontinuation of Long-Term Benzodiazepine Use in Insomnia and Anxiety Disorders > 2. Benzodiazepine Use and Abuse > 2.3. Recommendations for Use
What the sources say
- Partly supportedcites [66] Vissers, 2007, Is Melatonin Helpful in Stopping the Long-Term Use of Hypnotics? A Discontinuation Trial, Pharm. World Sci. sourceExperimental — accuracy not yet measured
The Results report nearly identical one-year benzodiazepine discontinuation rates with melatonin and placebo (8/20 versus 7/18), with no significant difference. But this source is a discontinuation trial, not a review, and its Abstract Conclusion says the findings are inconclusive, particularly because the participants' average benzodiazepine dose was low. It therefore supports a lack of demonstrated added benefit in this trial, not the claim that reviews establish no added value generally. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [67] Wright, 2015, The Effect of Melatonin on Benzodiazepine Discontinuation and Sleep Quality in Adults Attempting to Discontinue Benzodiazepines: A Systematic Review and Meta-Analysis, Drugs Aging source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
47 more claims · 9 with their cited sources checked
Create a free account to see all 135 claims and to verify the 4 references still open.
- It may state two separate claims as one. 56
- Probably not a substantial claim. 46
Citations
Cites
The Transtheoretical Model of Health Behavior Change.
Prochaska, J. O., & Velicer, W. F. (1997) · American Journal of Health Promotion · doi:10.4278/0890-1171-12.1.38 · Cited by 7,782
Hayes, S. C., Wilson, K. G., Gifford, E. V., Follette, V. M., & Strosahl, K. (1996) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.64.6.1152 · Cited by 3,595
Hoffman, S. G., & Smits, J. A. J. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0415 · Cited by 1,420
Psychological and behavioral treatment of insomnia: update of the recent evidence (1998-2004)
Morin, C. M., Bootzin, R. R., Buysse, D. J., Edinger, J. D., Espie, C. A., & Lichstein, K. L. (2006) · Sleep · doi:10.1093/sleep/29.11.1398 · Cited by 1,345
Dilute Concentrations of a Psychiatric Drug Alter Behavior of Fish from Natural Populations
Brodin, T., Fick, J., Jonsson, M., & Klaminder, J. (2013) · Science · doi:10.1126/science.1226850 · Cited by 850 · cited 1×
“A study published in the Science journal reveals that concentrations of benzodiazepines in water effluents affect the behavior of fish and disrupt the food chain, with potentially serious evolutionary consequences [48].”
BackgroundBenzodiazepine Use in the United States
Olfson, M., King, M., & Schoenbaum, M. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1763 · Cited by 786
Hayes, S. C. (2016) · Behavior Therapy · doi:10.1016/j.beth.2016.11.006 · Cited by 785
Efficacy of the third wave of behavioral therapies: A systematic review and meta- analysis
Öst, L.-G. (2008) · Behaviour Research and Therapy · doi:10.1016/j.brat.2007.12.005 · Cited by 727
Zachariae, R., Lyby, M. S., Ritterband, L. M., & O'Toole, M. S. (2016) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2015.10.004 · Cited by 704 · cited 1×
“CBT-I is recognised as being the treatment of choice for insomnia [93], both in isolated form or as a comorbidity [94], in psychiatric populations [95], among the elderly [96,97], and delivered remotely [98].”
BackgroundTannenbaum, C., Martin, P., Tamblyn, R., Benedetti, A., & Ahmed, S. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.949 · Cited by 665
Research works printed but not linked: 5
- Group, B., and Press, P. (2017). British National Formulary, National Institute of Clinical Excellence.
- (2021, March 09). Canadian Agency for Drugs and Technology in Health Discontinuation Strategies for Patients with Long-Term Benzodiazepine Use: A Review of Clinical Evidence and Guidelines, Available online: http://www.ncbi.nlm.nih.gov/pubmed/26290934.
- Morin, C.M. (1993). Insomnia: Psychological Assessment and Management, Guilford Press.
- Barlow, D., and Crask, M. (1989). Mastery of Your Anxiety and Panic, Graywind Press.
- Hayes, S.C., Strosahl, K., and Wilson, K.G. (1999). Acceptance and Commitment Therapy: An Experiential Approach to Behavior Change, Guilford Press.
Cited by
Brunner, E., Chen, C.-Y. A., Klein, T., Maust, D., Mazer-Amirshahi, M., Mecca, M., Najera, D., Ogbonna, C., Rajneesh, K. F., Roll, E., et al. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09499-2 · Cited by 51
“157,166 Clinicians can also consider consulting with psychiatrists or sleep medicine specialists to help guide treatment plans.”
Immunomodulatory Role of CB2 Receptors in Emotional and Cognitive Disorders
Morcuende, Á., García‐Gutiérrez, M. S., Tambaro, S., Nieto, E. O., Manzanares, J., & Femenía, T. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.866052 · Cited by 45
Ellis, J. G., Ferini‐Strambi, L., García-Borreguero, D., Heidbreder, A., O’Regan, D., Parrino, L., Selsick, H., & Penzel, T. (2023) · Healthcare · doi:10.3390/healthcare11050716 · Cited by 56
“6% of the French population took benzodiazepines for sleep problems [116].”
BackgroundZhu, X., Luo, T., Wang, D., Zhao, Y., Jin, Y., & Yang, G. (2023) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2023.165732 · Cited by 45
Gkintoni, E., & Νικολάου, Γ. (2024) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph21081110 · Cited by 40
“The affective component uses various therapeutic methods designed to cope with emotions [62–64].”
Background
Metadata
- Authors
- Chapoutot, M., Peter-Derex, L., Bastuji, H., Leslie, W., Schoendorff, B., Heinzer, R., Siclari, F., Nicolas, A., Lemoine, P., Higgins, S., Bourgeois, A., Vallet, G. T., Anders, R., Ounnoughene, M., Spencer, J., Meloni, F., & Putois, B.
- Affiliations
- Lyon 1 Université (FR)
- Association Nationale de Promotion des Connaissances sur Le Sommeil, 69001 Lyon, France
- Xceltranslate, 06000 Nice, France
- Institut de Psychologie Contextuelle, Montreal, QC H2Y 2S9, Canada
- Centre Hospitalier Universitaire Vaudois (CH)
- Centre Hospitalier Annecy Genevois (FR)
- University of Geneva (CH)
- Centre National de la Recherche Scientifique (FR)
- Université Lumière Lyon 2 (FR)
- Cabinet de Psychiatrie du Plateau de Haye, 54320 Maxéville, France
- UniDistance Suisse (CH)
- Corresponding author
- Putois, Benjamin
- ORCID
- Venue
- International Journal of Environmental Research and Public Health
- Publisher
- MDPI AG
- Published
- 2021-09-28
- Volume
- 18
- Issue
- 19
- Pages
- 10222
- ISSN
- 1660-4601 (ISSN-L)
- PMC
- PMC8508349
- OpenAlex
- W3204225041
- Cited by
- 59
- References
- 158
- Citations by year
- 2026: 9 · 2025: 20 · 2024: 10 · 2023: 17 · 2022: 3
- FWCI
- 1.23
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Environmental Research and Public Health (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- SERVAL (Université de Lausanne) (publishedVersion, cc-by)
- Le dépôt institutionnel (Université du Québec à Trois-Rivières) (submittedVersion)
- IRIS (submittedVersion, cc-by)
- HAL (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- FONDATION ALCEA (XXX)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Clinical Psychology › Mindfulness and Compassion Interventions
- Keywords
- benzodiazepine discontinuation, cognitive behavioral therapy, acceptance and commitment therapy, insomnia, anxiety disorders, benzodiazepine withdrawal, benzodiazepine dependence, substance use disorders, chronic sleep disorders
- MeSH terms
- Anxiety Disorders, Benzodiazepines, Humans, Sleep Initiation and Maintenance Disorders, Substance Withdrawal Syndrome, Cognitive Behavioral Therapy, Acceptance and Commitment Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cognitive Behavioral Therapy and Acceptance and Commitment Therapy for the Discontinuation of Long-Term Benzodiazepine Use in Insomnia and Anxiety Disorders. https://app.cochat.ai/papers/10.3390/ijerph181910222
- The paper
- Chapoutot, M., Peter-Derex, L., Bastuji, H., Leslie, W., Schoendorff, B., Heinzer, R., Siclari, F., Nicolas, A., Lemoine, P., Higgins, S., Bourgeois, A., Vallet, G. T., Anders, R., Ounnoughene, M., Spencer, J., Meloni, F., & Putois, B. (2021). Cognitive Behavioral Therapy and Acceptance and Commitment Therapy for the Discontinuation of Long-Term Benzodiazepine Use in Insomnia and Anxiety Disorders. International Journal of Environmental Research and Public Health. https://doi.org/10.3390/ijerph181910222
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.